HUMAN iPSC-DERIVED BRAIN ORGANOIDS AND USES THEREOF
AssigneeCity of Hope
InventorsYanhong SHI, Guoqiang SUN, Xianwei CHEN
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of producing human iPSC-derived brain organoids and uses thereof to detect and develop treatment for HCMV-induced brain deformation in developing fetus.
Claims17
A method of treating or preventing a neurodevelopmental deficit or HCMV-induced brain malformation in a developing fetus, comprising administering to the mother carrying the fetus a therapeutically effective amount of:
- one or more neutralizing antibodies that target HCMV pentamer complex;
- one or more neutralizing antibodies that target HCMV gH;
- a vaccine comprising the HCMV pentamer complex and capable of eliciting neutralizing antibodies;
- a vaccine comprising gH and capable of eliciting neutralizing antibodies;
- a platelet-derived growth factor receptor alpha (PDGFRα) inhibitor;
- an epidermal growth factor receptor (EGFR) inhibitor;
- or
- a combination thereof,
- wherein the mother is infected by HCMV or at an elevated risk of HCMV infection, and
- wherein the HCMV pentamer complex comprises gH, gL, UL128, UL130, and UL131A.
A combinational therapy for treating or preventing a neurodevelopmental deficit or HCMV-induced brain malformation in a developing fetus, comprising administering to the mother carrying the fetus two or more of (i) one or more neutralizing antibodies that target HCMV pentamer complex, (ii) one or more neutralizing antibodies that target HCMV gH, (iii) a vaccine comprising HCMV gH and capable of eliciting neutralizing antibodies, (iv) a vaccine comprising HCMV pentamer complex and capable of eliciting neutralizing antibodies, (v) one or more PDGFRα inhibitors, and (vi) one or more EGFR inhibitors, wherein the mother is infected by HCMV or at an elevated risk of HCMV infection, and wherein the HCMV pentamer complex comprises gH, gL, UL128, UL130, and UL131A.
Dependencies are inferred from the claim text.